Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Felzartamab for IgA Nephropathy
Recruiting0 awardsPhase 2
Rochester, Minnesota
This trial is testing a new drug for IgA Nephropathy, a kidney disease. The trial is comparing the new drug to a placebo, and is double-blind, meaning neither the patients nor the researchers know who is receiving which treatment.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.